Twentieth century toxinology and antivenom development in Australia.
It was not until the last decade of the 19th century that an experimental approach (led by Bancroft in Queensland and Martin in Sydney and Melbourne) brought a higher plane of scientific objectivity to usher in the modern era of Australian toxinology. This Australia era, 1895-1905, coincided with and in some respects was the result of the new knowledge emerging from Europe and the Americas of the therapeutic effects of antitoxins. The subsequent systematic study of Australian venoms and toxins through to the 1930s and beyond, by Tidswell, Fairley, Ross, Kellaway and Cleland, set the foundation for Australia's leading reputation in venom research. As elsewhere, this development was to revolutionise the medical management of those victims who in the past had died in Australia from our venomous and toxic fauna. Morgan, Graydon, Weiner, Lane and Baxter at the Commonwealth Serum Laboratories emphasised the importance of cooperation between those expert at catching and milking the venomous creatures and those developing the antivenoms. Commercial antivenom manufacture began in Australia in 1930 with the tiger snake antivenom. This was followed by other antivenoms for the other important species (1955: taipan; 1956: brown snake; 1958: death adder; 1959: Papuan black snake; 1961: sea snake; 1962: polyvalent) including the first marine antivenoms in the world (1956: stonefish antivenom; 1970: box jellyfish) culminating, in 1980, with the release of the funnel web spider antivenom. More recent activity has focused on veterinary antivenoms and production of new generation human antivenoms for export (CroFab and ViperaTAB). This paper reviews some of the milestones of Australian toxinology, and antivenom development in particular, during the 20th century.
Winkel
Kenneth D
KD
Australian Venom Research Unit, Department of Pharmacology, University of Melbourne, Parkville, Vic 3010, Australia. kdw@unimelb.edu.au
Mirtschin
Peter
P
Pearn
John
J
D000818:Animals; D000997:Antivenins / Q000266:history* / Q000627:therapeutic use; D001315:Australia; D037462:Cubozoa / Q000472:pathogenicity; D049672:History, 19th Century; D049673:History, 20th Century; D006801:Humans; D010947:Plants, Toxic / Q000009:adverse effects*; D012909:Snake Bites / Q000266:history* / Q000628:therapy; D012910:Snake Venoms / Q000266:history*; D014116:Toxicology / Q000266:history*
D000997:Antivenins; D012910:Snake Venoms